3 Stocks Dragging In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 5 points (0.0%) at 16,485 as of Friday, Dec. 27, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,370 issues advancing vs. 1,569 declining with 149 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is unchanged. Top gainers within the industry include Shire ( SHPG), up 1.2%, GlaxoSmithKline ( GSK), up 1.0%, Novo Nordisk A/S ( NVO), up 0.8%, Amgen ( AMGN), up 0.6% and Celgene Corporation ( CELG), up 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Biogen Idec ( BIIB) is one of the companies pushing the Drugs industry lower today. As of noon trading, Biogen Idec is down $2.65 (-0.9%) to $278.69 on light volume. Thus far, 228,446 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $278.60-$282.92 after having opened the day at $281.81 as compared to the previous trading day's close of $281.34.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $66.3 billion and is part of the health care sector. Shares are up 92.2% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.33 (-0.6%) to $53.27 on light volume. Thus far, 1.4 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7.2 million shares. The stock has ranged in price between $53.08-$53.80 after having opened the day at $53.66 as compared to the previous trading day's close of $53.60.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $87.6 billion and is part of the health care sector. Shares are up 64.5% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, solid stock price performance, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $0.59 (-0.8%) to $74.61 on light volume. Thus far, 2.1 million shares of Gilead exchanged hands as compared to its average daily volume of 10.6 million shares. The stock has ranged in price between $74.25-$75.36 after having opened the day at $75.36 as compared to the previous trading day's close of $75.20.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $114.9 billion and is part of the health care sector. Shares are up 104.8% year to date as of the close of trading on Thursday. Currently there are 16 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

Building in Biotech, Adding to Twitter

Building in Biotech, Adding to Twitter

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI